Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab in BRCA1/2 Carriers Scheduled for RRSO
NCT03382574Phase 1Terminated
- Sponsor
- National Cancer Institute
- Start
- Mar 2019
- Primary completion
- Oct 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of denosumab in ovarian carcinoma (2 arms), sponsored by National Cancer Institute. Primary endpoint: Ki67 Proliferation Index Fallopian Tube Fimbrial Epithelial Cells up to 12 months. Started Mar 2019; status: terminated.
02
Drugs
denosumab
03
Conditions
ovarian carcinoma
Beyond the preview
Go deeper on NCT03382574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03382574.